FORWARD THINKING HEALTHCARE

Transcription

1 AT A 2018 GLANCE

2 02 FORWARD THINKING HEALTHCARE Fresenius is a global healthcare group offering high-quality products and services for dialysis, hospitals, and outpatient treatment. With over 270,000 employees in more than 100 countries around the globe, and annual sales exceeding 33 billion, Fresenius is one of the world s leading healthcare companies. At Fresenius, the patient always comes first. For more than 100 years now we have been working to save lives and improve the quality of life of our patients. A clear focus on innovation and efficiency has helped us to make high-quality healthcare accessible to a steadily increasing number of people. Yet we never get complacent about our successes, and never stop looking for better solutions. This is how Fresenius is contributing to medical progress and better patient care. Success in our business is the key for investing in high-quality yet affordable healthcare. In this way we are meeting our social responsibility to help patients, while ensuring that Fresenius remains successful over the long term.

3 05 OUR YEAR 2017 ENTRY INTO BIOSIMILARS HELP FOR HURRICANE VICTIMS Fresenius Kabi acquired the biosimilars business of Germany s Merck, with a product pipeline focused on oncology and autoimmune diseases, in September. A biosimilar is a drug that is similar to another biologic drug already approved. After catastrophic hurricanes hit the Southeastern U.S. coast, Mexico and the Caribbean in late summer, Fresenius employees made tremendous efforts to treat patients and maintain the production of essential medical products. REHABILITATION OFFERING EXPANDED In November, Fresenius Vamed acquired a rehabilitation clinic in Seewis, Switzerland that specializes in heart disease, internal medicine and psychosomatic illnesses. FRESENIUS WELCOMES QUIRÓNSALUD On February 1, we welcomed 35,000 new colleagues from Quirónsalud into the Fresenius family. With 90 hospitals and outpatient centers, Quirónsalud is Spain s largest private hospital operator. EXPANSION IN HOME DIALYSIS Fresenius Medical Care announced the acquisition of NxStage Medical in early August. This U.S.-based company develops and produces medical devices used in home dialysis and critical care. INVESTING IN OUR HOSPITALS Helios opened new hospital buildings last year in the German cities of Duisburg and Nordenham. Quirónsalud expanded the university hospital in Madrid, and is building a brand new hospital in nearby Alcalá de Henares. HEADQUARTERS EXPANSION In September, Fresenius laid the cornerstone for a new office building, part of our headquarters expansion in Bad Homburg, Germany. The new building will have around 600 modern office workplaces, to help accommodate the steadily increasing number of Fresenius employees.

4 07 GROUP RESULTS IN MILLIONS (IFRS) million 550 Fresenius invests more than annually in research and development. Sales and Earnings in millions Sales 33,886 29,471 27,995 EBIT 4,830 4,302 4,001 EBIT margin 14.3 % 14.6 % 14.3 % Net income 1,816 1,560 1,436 Operating cash flow 3,937 3,585 3,349 Shares Number of shares 554,710, ,208, ,727,950 Market capitalization in millions 36,095 40,636 36,002 Per share in Dividend 0.75* Earnings *Subject to approval by the Annual General Meeting on May 18, 2018 Balance Sheet in millions Total assets 53,133 46,697 43,233 Equity ratio 41 % 45 % 43 % Debt ratio Net debt/ebitda Investments 8,680 2,559 2,051 Employees Employees (Dec. 31) 273, , ,305 Fresenius Vamed 3 % of Group sales Fresenius Kabi 19 % of Group sales Fresenius Helios 26 % of Group sales SALES 33.9 BILLION Fresenius Medical Care 52 % of Group sales

5 09 PRODUCTS AND SERVICES FOR INDIVIDUALS WITH RENAL DISEASES Every second dialysis machine used around the world is from Fresenius Medical Care. Key Figures in millions Change Sales 17,784 16,570 7 % EBIT 2,493 2,409 4 % Net income 1,204 1,144 5 % Operating cash flow 2,192 1, % Capital expenditure/ acquisitions 1,627 1,705-5 % R & D expenses % Employees (Dec. 31) 121, ,120 4 % Fresenius Medical Care is the world s largest provider of products and services for individuals with renal diseases of which more than 3 million patients worldwide regularly undergo dialysis treatment. Through its network of more than 3,700 dialysis clinics, Fresenius Medical Care provides dialysis treatments for over 320,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of additional medical services in the field of Care Coordination. Every 0.7 seconds, Fresenius Medical Care starts a dialysis treatment somewhere in the world.

6 11 PRODUCTS FOR CRITICALLY AND CHRONICALLY ILL PATIENTS 90 Fresenius Kabi brought more than inexpensive I.V. generics to the market in Key Figures in millions Change Sales 6,358 6,007 6 % EBIT 1,177 1,171 1 % Net income % Operating cash flow 1,010 1,004 1 % Capital expenditure/ acquisitions % R & D expenses % Employees (Dec. 31) 36,380 34,917 4 % Fresenius Kabi is a global healthcare company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems. In the field of biosimilars, Fresenius Kabi develops products with a focus on oncology and autoimmune diseases. More than 1 billion infusion solutions are produced annually by Fresenius Kabi.

7 13 EUROPE S LEADING PRIVATE HOSPITAL OPERATOR Fresenius Helios treats more than17million patients annually, in its over 150 hospitals. Key Figures in millions Change Sales 8,668 5, % EBIT 1, % Net income % Operating cash flow % Capital expenditure/ acquisitions 6, Employees (Dec. 31) 105,927 72, % Fresenius Helios is Europe s leading private hospital operator, with more than 100,000 employees. Fresenius Helios owns and operates Helios hospitals in Germany and Quirónsalud hospitals in Spain. Both Helios and Quirónsalud are the largest private hospital operators in their respective national markets. Helios owns more than 100 hospitals across Germany including maximum care facilities in Berlin, Duisburg, Erfurt, Krefeld, Schwerin, Wiesbaden and Wuppertal. Quirónsalud operates over 40 hospitals, more than 40 outpatient centers and some 300 occupational risk prevention centers. 200 More than babies are born every day in Fresenius Helios hospitals.

8 15 PROJECTS AND SERVICES FOR HEALTH CARE FACILITIES 800 Fresenius Vamed has successfully completed more than projects worldwide. Key Figures in millions Change Sales 1,228 1,160 6 % EBIT % Net income % Operating cash flow % Capital expenditure/ acquisitions Order intake 1,096 1,017 8 % Employees (Dec. 31) 8,667 8,198 6 % Fresenius Vamed is a global provider of services in planning, con structing and managing health care facilities. With its approach of everything from one source, the company offers a complete value chain to achieve and maintain efficiency at every stage: from project development, planning and turnkey construction to facility and total operational management. Headquartered in Vienna, Austria, Fresenius Vamed boasts a track record of more than 800 completed health care projects in around 80 countries since its founding in Fresenius Vamed operates 9 thermal spas and wellness resorts in Austria and Hungary.

9 17 SALES BY REGION in billion 41 % Europe 56 % North America 45 % 27 % Latin America and Africa 5 % 8 % Asia-Pacific 9 % 9 % EMPLOYEES BY REGION at end of ,249

10 FROM A LOCAL PHARMACY TO A GLOBAL CORPORATION 1462 OPENING OF THE HIRSCH PHARMACY IN FRANKFURT In the 19th century, ownership of the pharmacy passes to the Fresenius family DISTRIBUTOR OF DIALYSIS MACHINES Fresenius starts to sell dialysis machines and dialyzers manufactured by various non-german companies ENTRY INTO PROJECT BUSINESS With the acquisition of Hospitalia International, Fresenius enters the project business for developing hospitals and other healthcare facilities EXPANSION OF HOSPITAL BUSINESS Fresenius acquires Helios, one of Germany s leading private hospital operators FRESENIUS CELEBRATES COMPANY S CENTENNIAL On its 100th anniversary, Fresenius is active in some 100 countries and has more than 160,000 employees FOUNDING OF THE COMPANY The pharmacist Dr. Eduard Fresenius, proprietor of the Hirsch Pharmacy, establishes the pharmaceutical company Dr. E. Fresenius ELSE KRÖNER ASSUMES MANAGEMENT OF FRESENIUS The foster daughter of Eduard Fresenius, she will, along with her future husband Hans Kröner, over the next decades build the company into global healthcare group DEATH OF THE COMPANY S FOUNDER, EDUARD FRESENIUS 1986 FRESENIUS LISTED ON STOCK MARKET 1979 DEVELOPMENT AND SALE OF COMPANY S OWN DIALYSIS MACHINES Production of the A2008 dialysis machine begins in a newly acquired factory in Schweinfurt, Germany ENTRY INTO DIALYSIS SERVICES Fresenius Medical Care is created when the U.S. dialysis provider National Medical Care, acquired by Fresenius, is merged with Fresenius own dialysis business. The project business is expanded with the acquisition of VAMED AG. of APP Pharmaceuticals EXPANSION OF INFUSIONS BUSINESS The nutrition business of Pharmacia & Upjohn is acquired and then merged with Fresenius Pharma to form Fresenius Kabi EXPANSION IN I.V. GENERICS Fresenius Kabi enters the North American pharmaceuticals market through the acquisition 2017 HOSPITAL NETWORK EXPANDED OUTSIDE OF GERMANY Fresenius Helios acquires Quirónsalud, Spain s largest private hospital operator.

11

12 Fresenius SE & Co. KGaA Else-Kröner-Str Bad Homburg Germany T Contact for Journalists Corporate Communications T pr-fre@fresenius.com Contact for Shareholders Investor Relations T ir-fre@fresenius.com Contact for Job Applicants HR Marketing careers@fresenius.com Some figures are adjusted for special items. Net income = Net income attributable to the parent company of the respective business segment.